Ind-Swift Laboratories Ltd.

₹395.15

6.4 (1.6%)

INDSWFTLAB Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 3,437.16 Cr

P/E Ratio79.57

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	401.89	Bearish
10-DMA	397.4	Bearish
20-DMA	386.6	Bullish
50-DMA	327.62	Bullish
100-DMA	254.11	Bullish
200-DMA	189.22	Bullish

Historical Performance

1 Year

305.8%

3 Years

337.4%

5 Years

518.4%

10 Years

946.8%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	6,491	5,742	12,809	12,073	10,387
Total Expenditure	6,124	5,811	10,267	9,781	8,431
Other Income	571	689	454	335	435
Operating Profit	938	620	2,996	2,627	2,391
Interest	14	29	511	922	955
Depreciation	306	245	533	574	1,310
Profit Before Tax	508	2,578	5,818	865	125
Consolidated Net Profit	431	2,505	4,210	476	-21
Adjusted EPS	5	36	71	8	---

Compounded Sales Growth

10 Years:-0.1

5 Years:-6.1

3 Years:-11.7

TTM:2.5

Compounded Profit Growth

10 Years:-23.9

5 Years:36.6

3 Years:-2

TTM:-29.7

Stock Price CAGR

10 Years:25

5 Years:44

3 Years:62.8

TTM:306.7

Return on Equity

10 Years:-8.7

5 Years:-0.4

3 Years:71.2

last year:5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	868	687	591	598	598
Total Reserves	12,963	10,302	8,724	6,221	5,412
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	-182	2	-195	7,412	8,136
Other Current Liabilities	1,048	988	228	1,057	891
Short Term Borrowings	37	56	27	492	640
Total Liabilities	16,230	13,937	11,332	17,942	17,489
Capital Work in Progress	102	---	---	77	93
Long Term Loans & Advances	944	813	3,539	42	40
Currents Investments	119	394	---	---	---
Short Term Loans and Advances	1,716	1,147	496	1,920	1,516
Total Current Assets	9,768	8,653	6,611	11,631	10,733
Total Assets	16,230	13,937	11,332	17,942	17,489
Adjusted Book Value	159	160	158	84	68

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 79.57, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 62.8%, indicating sustained price appreciation.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹938 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6491 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 4063656.9

No. of Shares: 10284 (Approx)

Performance:306.4%

3063656.9

NIFTY Performance: -9.9%

1 day Top Gainers